MiNK Therapeutics, Inc. (INKT) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
149 FIFTH AVENUE NEW YORK, NY 10010 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 19,636 | 38,889 | ||
| Cash and cash equivalents | 19,636 | 38,889 | ||
| Receivables | 23 | |||
| Prepaid expense | 299 | 2 | ||
| Other current assets | 470 | 744 | ||
| Other undisclosed current assets | (23) | |||
| Total current assets: | 20,405 | 39,635 | ||
| Noncurrent Assets | ||||
| Property, plant and equipment | 1,067 | 607 | ||
| Total noncurrent assets: | 1,067 | 607 | ||
| TOTAL ASSETS: | 21,472 | 40,242 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 10,062 | 4,759 | ||
| Accounts payable | 5,823 | 2,996 | ||
| Accrued liabilities | 4,239 | 1,764 | ||
| Due to related parties | 5,945 | |||
| Other liabilities | 2,622 | 5,761 | ||
| Total current liabilities: | 12,683 | 16,465 | ||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 9,190 | |||
| Due to related parties | 9,081 | |||
| Other liabilities | 109 | |||
| Total noncurrent liabilities: | 9,190 | |||
| Total liabilities: | 21,873 | 16,465 | ||
| Equity | ||||
| Equity, attributable to parent | (401) | 23,776 | ||
| Common stock | 0 | 0 | ||
| Additional paid in capital | 110,830 | 107,349 | ||
| Accumulated other comprehensive loss | (292) | (625) | ||
| Accumulated deficit | (110,939) | (82,948) | ||
| Total equity: | (401) | 23,776 | ||
| TOTAL LIABILITIES AND EQUITY: | 21,472 | 40,242 | ||
Income Statement (P&L) ($ in thousands)
| 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|
| Operating expenses | (30,949) | (18,606) | |
| Other undisclosed operating loss | (9,752) | ||
| Operating loss: | (30,949) | (28,359) | |
| Nonoperating income (expense) | 2,691 | (185) | |
| Loss, foreign currency transaction, before tax | (14) | (407) | |
| Other nonoperating income | 2,705 | 222 | |
| Interest and debt expense | (2,076) | ||
| Loss from continuing operations: | (28,259) | (30,620) | |
| Loss before gain (loss) on sale of properties: | ✕ | (30,620) | |
| Other undisclosed net income | 267 | 407 | |
| Net loss available to common stockholders, diluted: | (27,991) | (30,213) | |
Comprehensive Income ($ in thousands)
| 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|
| Net loss: | (27,991) | (30,213) | |
| Other comprehensive income | 333 | 898 | |
| Comprehensive loss, net of tax, attributable to parent: | (27,658) | (29,315) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.